دورية أكاديمية
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors. Insights from the SGLT2-I AMI PROTECT study
العنوان: | In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors. Insights from the SGLT2-I AMI PROTECT study |
---|---|
المؤلفون: | Cesaro A., Gragnano F., Paolisso P., Bergamaschi L., Gallinoro E., Sardu C., Mileva N., Foa A., Armillotta M., Sansonetti A., Amicone S., Impellizzeri A., Esposito G., Morici N., Oreglia J. A., Casella G., Mauro C., Vassilev D., Galie N., Santulli G., Pizzi C., Barbato E., Calabro P., Marfella R. |
المساهمون: | Cesaro, A., Gragnano, F., Paolisso, P., Bergamaschi, L., Gallinoro, E., Sardu, C., Mileva, N., Foa, A., Armillotta, M., Sansonetti, A., Amicone, S., Impellizzeri, A., Esposito, G., Morici, N., Oreglia, J. A., Casella, G., Mauro, C., Vassilev, D., Galie, N., Santulli, G., Pizzi, C., Barbato, E., Calabro, P., Marfella, R. |
بيانات النشر: | Frontiers Media S.A. |
سنة النشر: | 2022 |
المجموعة: | Sapienza Università di Roma: CINECA IRIS |
مصطلحات موضوعية: | acute myocardial infarction, atrial fibrillation, hyperglycemia, sodium-glucose cotransporter 2 inhibitors (sglt2-i), ventricular arrhythmia, ventricular tachycardia |
الوصف: | Background Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM). They have also gained interest for their potential anti-arrhythmic role and their ability to reduce the occurrence of atrial fibrillation (AF) and ventricular arrhythmias (VAs) in T2DM and heart failure patients. Objectives To investigate in-hospital new-onset cardiac arrhythmias in a cohort of T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-i vs. other oral anti-diabetic agents (non-SGLT2-i users). Methods Patients from the SGLT2-I AMI PROTECT registry (NCT05261867) were stratified according to the use of SGLT2-i before admission for AMI, divided into SGLT2-i users vs. non-SGLT2-i users. In-hospital outcomes included the occurrence of in-hospital new-onset cardiac arrhythmias (NOCAs), defined as a composite of new-onset AF and sustained new-onset ventricular tachycardia (VT) and/or ventricular fibrillation (VF) during hospitalization. Results The study population comprised 646 AMI patients categorized into SGLT2-i users (111 patients) and non-SGLT2-i users (535 patients). SGLT2-i users had a lower rate of NOCAs compared with non-SGLT2-i users (6.3 vs. 15.7%, p = 0.010). Moreover, SGLT2-i was associated with a lower rate of AF and VT/VF considered individually (p = 0.032). In the multivariate logistic regression model, after adjusting for all confounding factors, the use of SGLT2-i was identified as an independent predictor of the lower occurrence of NOCAs (OR = 0.35; 95%CI 0.14-0.86; p = 0.022). At multinomial logistic regression, after adjusting for potential confounders, SGLT2-i therapy remained an independent predictor of VT/VF occurrence (OR = 0.20; 95%CI 0.04-0.97; p = 0.046) but not of AF occurrence. Conclusions In T2DM patients, the use of SGLT2-i was associated with a lower risk of new-onset arrhythmic events during hospitalization for AMI. In particular, the primary effect was expressed in the ... |
نوع الوثيقة: | article in journal/newspaper |
اللغة: | English |
العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36237914; info:eu-repo/semantics/altIdentifier/wos/WOS:000886102600001; volume:9; firstpage:1; lastpage:12; numberofpages:12; journal:FRONTIERS IN CARDIOVASCULAR MEDICINE; https://hdl.handle.net/11573/1699863Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85139557015 |
DOI: | 10.3389/fcvm.2022.1012220 |
الإتاحة: | https://doi.org/10.3389/fcvm.2022.1012220Test https://hdl.handle.net/11573/1699863Test |
حقوق: | info:eu-repo/semantics/openAccess |
رقم الانضمام: | edsbas.A58DAA42 |
قاعدة البيانات: | BASE |
DOI: | 10.3389/fcvm.2022.1012220 |
---|